Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 2, 2005, Pages 685-689

  Hermsen, Elizabeth D ^a   Hovde, Laurie B ^a   Sprandel, Kelly A ^b   Rodvold, Keith A ^b   Rotschafer, John C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTEROIDES FRAGILIS; BACTEROIDES INFECTIONS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONY COUNT, MICROBIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HALF-LIFE; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; OFLOXACIN; QUINOLINES;

EID: 12944300988     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.2.685-689.2005     Document Type: Article

References (14)

1. Behra-Miellet, J., L. Dubreuil, and E. Jumas-Bilak. 2002. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int. J. Antimicrob. Agents 20:366-374.
2. Brook, I. 1993. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities. Antimicrob. Agents Chemother. 37:997-1000.
3. Edmiston, C. E., C. J. Krepel, G. R. Seabrook, L. R. Somberg, A. Nakeeb, R. A. Cambria, and J. B. Towne. 2004. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob. Agents Chemother. 48:1012-1016.
4. Goldstein, E. J. 2002. Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin. Infect. Dis. 35:S106-S111.
5. Harnett, S. J., A. P. Fraise, J. M. Andrews, G. Jevons, N. P. Brenwald, and R. Wise. 2004. Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492. J. Antimicrob. Chemother. 53:783-792.
6. Ingham, H. R., C. J. Hall, P. R. Sisson, D. Tharagonnet, and J. B. Selkon. 1980. The activity of metronidazole against facultatively anaerobic bacteria. J. Antimicrob. Chemother. 6:343-347.
7. Jessa, M. J., D. A. Barrett, P. N. Shaw, and R. C. Spiller. 1996. Rapid and selective high-performance liquid chromatographic method for the determination of metronidazole and its active metabolite in human plasma, saliva and gastric juice. J. Chromatogr. B Biomed. Appl. 677:374-379.
8. Onderdonk, A. B., T. J. Louie, F. P. Tally, and J. G. Bartlett. 1979. Activity of metronidazole against Escherichia coli in experimental intra-abdominal sepsis. J. Antimicrob. Chemother. 5:201-210.
9. Pendland, S. L., R. Jung, C. R. Messick, C. A. Schriever, and J. Patka. 2002. In vitro bactericidal activity of piperacillin, gentamicin, and metronidazole in a mixed model containing Escherichia coli, Enterococcus faecalis, and Bacteroides fragilis. Diagn. Microbiol. Infect. Dis. 43:149-156.
10. Peterson, M. L., L. B. Hovde, D. H. Wright, G. H. Brown, A. D. Hoang, and J. C. Rotschafer. 2002. Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 46:203-210.
11. Snydman, D. R., N. V. Jacobus, L. A. McDermott, R. Ruthazer, E. Goldstein, S. Finegold, L. Harrell, D. W. Hecht, S. Jenkins, C. Pierson, R. Venezia, J. Rihs, and S. L. Gorbach. 2002. In vitro activities of newer quinolones against Bacteroides group organisms. Antimicrob. Agents Chemother. 46:3276-3279.
12. Stearne, L. E., C. Kooi, W. H. Goessens, I. A. Bakker-Woudenberg, and I. C. Gyssens. 2001. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique. Antimicrob. Agents Chemother. 45:243-251.
13. Wright, D. H., V. K. Herman, F. N. Konstantinides, and J. C. Rotschafer. 1998. Determination of quinolone antibiotics in growth media by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 709:97-104.
14. Zabinski, R. A., K. Vance-Bryan, A. J. Krinke, K. J. Walker, J. A. Moody, and J. C. Rotschafer. 1993. Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system. Antimicrob. Agents Chemother. 37:2454-2458.